• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $PNT

    POINT Biopharma Global Inc.

    Subscribe to $PNT
    $PNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    POINT Biopharma Global Inc., a late-stage clinical precision oncology company, focuses on the development and commercialization of radiopharmaceuticals for the treatment of cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer; and PNT-2004, a fibroblast activation protein-a targeted radioligand to treat solid tumors. POINT Biopharma Global Inc. is based in Indianapolis, Indiana.

    IPO Year: 2020

    Exchange: NASDAQ

    Website: pointbiopharma.com

    Peers

    $NMTR
    $OYST

    Recent Analyst Ratings for POINT Biopharma Global Inc.

    DatePrice TargetRatingAnalyst
    7/20/2023$12.00 → $14.00Buy
    Jefferies
    12/14/2022$10.00Outperform
    Raymond James
    11/30/2022$14.00Outperform
    SVB Leerink
    10/11/2022$20.00Outperform
    Oppenheimer
    9/16/2022$22.00Buy
    Truist
    9/14/2022$20.00Buy
    Berenberg
    8/16/2022$20.00Buy
    Guggenheim
    7/6/2022Outperform
    William Blair
    5/26/2022$7.00 → $20.00Hold → Buy
    Jefferies
    12/17/2021$65.00Underperform
    Mizuho
    See more ratings

    POINT Biopharma Global Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Goodman Jonathan R.

      4 - POINT Biopharma Global Inc. (0001811764) (Issuer)

      12/27/23 5:41:13 PM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Kelly Justyna

      4 - POINT Biopharma Global Inc. (0001811764) (Issuer)

      12/27/23 5:40:48 PM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mccann Joe A. closing all direct ownership in the company (SEC Form 4)

      4 - POINT Biopharma Global Inc. (0001811764) (Issuer)

      12/27/23 5:40:37 PM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Jensen Jessica D.

      4 - POINT Biopharma Global Inc. (0001811764) (Issuer)

      12/27/23 5:39:53 PM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fleshner Neil E. closing all direct ownership in the company (SEC Form 4)

      4 - POINT Biopharma Global Inc. (0001811764) (Issuer)

      12/27/23 5:39:23 PM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hogue Gerald L. closing all direct ownership in the company (SEC Form 4)

      4 - POINT Biopharma Global Inc. (0001811764) (Issuer)

      12/27/23 5:37:48 PM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Malik Rajesh closing all direct ownership in the company (SEC Form 4)

      4 - POINT Biopharma Global Inc. (0001811764) (Issuer)

      12/27/23 5:37:35 PM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lubner David Charles returned 3,600 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - POINT Biopharma Global Inc. (0001811764) (Issuer)

      12/27/23 5:37:18 PM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Demers William L.

      4 - POINT Biopharma Global Inc. (0001811764) (Issuer)

      12/27/23 5:36:35 PM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Silber Allan C

      4 - POINT Biopharma Global Inc. (0001811764) (Issuer)

      12/27/23 5:35:38 PM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    POINT Biopharma Global Inc. SEC Filings

    See more
    • SEC Form 15-12G filed by POINT Biopharma Global Inc.

      15-12G - POINT Biopharma Global Inc. (0001811764) (Filer)

      1/8/24 7:00:48 AM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by POINT Biopharma Global Inc.

      EFFECT - POINT Biopharma Global Inc. (0001811764) (Filer)

      1/3/24 12:15:04 AM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by POINT Biopharma Global Inc.

      EFFECT - POINT Biopharma Global Inc. (0001811764) (Filer)

      1/3/24 12:15:10 AM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POS AM filed by POINT Biopharma Global Inc.

      POS AM - POINT Biopharma Global Inc. (0001811764) (Filer)

      12/27/23 9:44:55 AM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POS AM filed by POINT Biopharma Global Inc.

      POS AM - POINT Biopharma Global Inc. (0001811764) (Filer)

      12/27/23 9:43:50 AM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by POINT Biopharma Global Inc.

      S-8 POS - POINT Biopharma Global Inc. (0001811764) (Filer)

      12/27/23 9:42:25 AM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by POINT Biopharma Global Inc.

      S-8 POS - POINT Biopharma Global Inc. (0001811764) (Filer)

      12/27/23 9:41:25 AM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by POINT Biopharma Global Inc.

      S-8 POS - POINT Biopharma Global Inc. (0001811764) (Filer)

      12/27/23 9:39:55 AM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by POINT Biopharma Global Inc.

      25-NSE - POINT Biopharma Global Inc. (0001811764) (Subject)

      12/27/23 9:26:22 AM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • POINT Biopharma Global Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Financial Statements and Exhibits

      8-K - POINT Biopharma Global Inc. (0001811764) (Filer)

      12/27/23 8:54:31 AM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    POINT Biopharma Global Inc. Financials

    Live finance-specific insights

    See more

    POINT Biopharma Global Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lilly Completes Acquisition of POINT Biopharma

      INDIANAPOLIS, Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ:PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. "Next generation radioligand therapies hold great promise for delivering meaningful advances against a range of cancers and we are excited to enter this space through the addition of POINT," said Jacob Van Naarden, executive vice president and president, Loxo@Lilly. "We welcome POINT colleagues to Lilly and look forward to working together to build on their work as we

      12/27/23 8:31:00 AM ET
      $LLY
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on POINT Biopharma with a new price target

      Jefferies resumed coverage of POINT Biopharma with a rating of Buy and set a new price target of $14.00 from $12.00 previously

      7/20/23 8:29:09 AM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James initiated coverage on POINT Biopharma with a new price target

      Raymond James initiated coverage of POINT Biopharma with a rating of Outperform and set a new price target of $10.00

      12/14/22 8:57:40 AM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink initiated coverage on POINT Biopharma with a new price target

      SVB Leerink initiated coverage of POINT Biopharma with a rating of Outperform and set a new price target of $14.00

      11/30/22 8:41:36 AM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on POINT Biopharma with a new price target

      Oppenheimer initiated coverage of POINT Biopharma with a rating of Outperform and set a new price target of $20.00

      10/11/22 7:52:35 AM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Truist initiated coverage on POINT Biopharma with a new price target

      Truist initiated coverage of POINT Biopharma with a rating of Buy and set a new price target of $22.00

      9/16/22 7:42:43 AM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berenberg initiated coverage on POINT Biopharma with a new price target

      Berenberg initiated coverage of POINT Biopharma with a rating of Buy and set a new price target of $20.00

      9/14/22 7:31:19 AM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on POINT Biopharma with a new price target

      Guggenheim initiated coverage of POINT Biopharma with a rating of Buy and set a new price target of $20.00

      8/16/22 7:55:53 AM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • William Blair initiated coverage on POINT Biopharma

      William Blair initiated coverage of POINT Biopharma with a rating of Outperform

      7/6/22 7:46:53 AM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • POINT Biopharma upgraded by Jefferies with a new price target

      Jefferies upgraded POINT Biopharma from Hold to Buy and set a new price target of $20.00 from $7.00 previously

      5/26/22 7:37:40 AM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mizuho initiated coverage on POINT Biopharma Global with a new price target

      Mizuho initiated coverage of POINT Biopharma Global with a rating of Underperform and set a new price target of $65.00

      12/17/21 7:01:55 AM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    POINT Biopharma Global Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors

      Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa

      5/28/24 9:30:00 AM ET
      $ACHV
      $ALGS
      $DCTH
      $PNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Medical/Dental Instruments
    • Lilly Completes Acquisition of POINT Biopharma

      INDIANAPOLIS, Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ:PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. "Next generation radioligand therapies hold great promise for delivering meaningful advances against a range of cancers and we are excited to enter this space through the addition of POINT," said Jacob Van Naarden, executive vice president and president, Loxo@Lilly. "We welcome POINT colleagues to Lilly and look forward to working together to build on their work as we

      12/27/23 8:31:00 AM ET
      $LLY
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

      Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company's Chief Business Officer REHOVOT, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced the appointment of Dr. Yael Margolin as an independent member of the Company's Board of Directors. Dr. Yael Margolin has more than 35 years of experience as senior manager, c

      12/20/23 8:05:00 AM ET
      $GMDA
      $PNT
      $PPBT
      $SCNI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer

      Phase 3 SPLASH study of 177Lu-PNT2002 demonstrated statistically significant improvement in radiographic progression-free survival (rPFS) BEDFORD, Mass., and INDIANAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- December 18, 2023 – Lantheus Holdings, Inc. (Lantheus) (NASDAQ:LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ:PNT) today announced statistically significant topline results from the pivotal Phase 3 SPLASH study evaluating the efficacy and safety of 177Lu-PNT2002, a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), in patients with metastatic castration-resistant prostate cancer (mCRPC) after progression on an androgen receptor pathway inhibitor (AR

      12/18/23 7:30:00 AM ET
      $LNTH
      $PNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023

      INDIANAPOLIS, Dec. 18, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ:PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire at 5:00 p.m., Eastern time, on Dec. 15, 2023, has been extended until 5:00 p.m., Eastern time, on Dec. 22, 2023, unless the tender offer is further extended or earlier terminated, in order for the parties to satisfy the minimum tender condition. All regulatory app

      12/18/23 6:45:00 AM ET
      $LLY
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023

      INDIANAPOLIS, Dec. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ:PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire at 5:00 p.m., Eastern time, on Dec. 1, 2023, has been extended until 5:00 p.m., Eastern time, on Dec. 15, 2023, unless the tender offer is further extended or earlier terminated, in order for the parties to satisfy the minimum tender condition. All regulatory appro

      12/4/23 6:45:00 AM ET
      $LLY
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023

      INDIANAPOLIS, Nov. 17, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ:PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire at 5:00 p.m., Eastern time, on Nov. 16, 2023, has been extended until 5:00 p.m., Eastern time, on Dec. 1, 2023, unless the tender offer is further extended or earlier terminated, in order for the parties to satisfy the minimum tender condition. All regulatory appr

      11/17/23 6:45:00 AM ET
      $LLY
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma

      INDIANAPOLIS, Nov. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Nuclear Regulatory Commission ("NRC") has issued its consent for the indirect transfer of control of POINT Biopharma Global Inc.'s (NASDAQ:PNT) radioactive materials license (the "NRC Consent"), which will occur following the completion of Lilly's previously announced tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT, for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. Obtaining the NRC Consent is the last regulatory approval necessary for the consummation of the transaction. The t

      11/14/23 4:33:00 PM ET
      $LLY
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights

      INDIANAPOLIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ:PNT) (the "Company" or "POINT"), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the third quarter ended September 30, 2023, and provided a business update. "The founding mission of our company is to accelerate the discovery, development and global access to radiopharmaceuticals," said Joe McCann, Ph.D., CEO of POINT Biopharma. "I view Lilly's agreement to acquire POINT as validation of the uniqueness of our team, infrastructure and pipeline. Together, we can become a global radiopharmaceutical leader, executi

      11/13/23 7:30:00 AM ET
      $LLY
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies

      INDIANAPOLIS, Oct. 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and POINT Biopharma Global, Inc. (NASDAQ:PNT) today announced a definitive agreement for Lilly to acquire POINT, a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. Radioligand therapy can enable the precise targeting of cancer by linking a radioisotope to a targeting molecule that delivers radiation directly to cancer cells, enabling significant anti-tumor efficacy while limiting the impact to healthy tissue. POINT's lead programs are in late-phase development. PNT20021 is a prostate-specific membrane antigen (PSMA) targete

      10/3/23 6:45:00 AM ET
      $LLY
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    POINT Biopharma Global Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors

      Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa

      5/28/24 9:30:00 AM ET
      $ACHV
      $ALGS
      $DCTH
      $PNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Medical/Dental Instruments
    • Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

      Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company's Chief Business Officer REHOVOT, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced the appointment of Dr. Yael Margolin as an independent member of the Company's Board of Directors. Dr. Yael Margolin has more than 35 years of experience as senior manager, c

      12/20/23 8:05:00 AM ET
      $GMDA
      $PNT
      $PPBT
      $SCNI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands

      INDIANAPOLIS and SCHLIEREN-ZURICH, Switzerland, Sept. 18, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ:PNT) (the "Company" or "POINT"), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, and Athebio AG ("Athebio"), an innovation leader in the discovery and design of designed ankyrin repeat proteins (DARPins), today announced a collaboration and license agreement to develop and commercialize DARPin-targeted radioligands ("Radio-DARPins"). DARPins are an attractive ligand class for cell-surface targets that could enable access to cell "surfaceome" targets beyond catalytic and ligand binding sites typically ac

      9/18/23 8:00:00 AM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • POINT Biopharma Announces Appointment of Dr. Bridget Martell to its Board of Directors

      INDIANAPOLIS, June 12, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ:PNT) (the "Company" or "POINT"), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the filling of its vacant board seat with the appointment of Bridget Martell, M.A., M.D. to its Board of Directors. "On behalf of POINT and the Board of Directors, I am pleased to welcome Dr. Martell, an experienced biotech board executive who brings extensive drug development, operational, and commercial expertise in both oncology and precision medicine," said Allan Silber, Executive Chairman of POINT Biopharma. "Her experience and perspectives will b

      6/12/23 8:00:00 AM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • POINT Biopharma announces appointment of Chris Horvath as EVP, Commercial

      Mr. Horvath will lead the commercialization of POINT's pipeline. He brings over a decade of experience in pharmaceutical commercialization, most recently as the VP and Head of Prostate Cancer Radioligand Therapy Franchise at Advanced Accelerator Applications (a Novartis Company) INDIANAPOLIS, June 21, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ:PNT) (the "Company" or "POINT"), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced the appointment of Chris Horvath, as Executive Vice President, Commercial. Mr. Horvath brings almost twenty years of experience in the pharmaceutical industry, having led or wo

      6/21/22 8:30:00 AM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • POINT Biopharma Adds Senior BD Expertise with Appointment of Dr. Matthew Vincent as SVP, Business Development

      INDIANAPOLIS, Jan. 04, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ:PNT) (the "Company" or "POINT"), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced the appointment of Matthew Vincent, Ph.D., J.D., as Senior Vice President, Business Development. Dr. Vincent brings more than 25 years of pharma business development experience through a variety of partnering, licensing, and M&A transactions and will lead licensing activities for POINT, with a focus on expansion into the Asian markets and strategic partnerships to fully realize the potential of POINT's pan-cancer targeting technologies. Dr. Vincent's d

      1/4/22 8:30:00 AM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    POINT Biopharma Global Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by POINT Biopharma Global Inc. (Amendment)

      SC 13D/A - POINT Biopharma Global Inc. (0001811764) (Subject)

      12/27/23 5:02:42 PM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by POINT Biopharma Global Inc. (Amendment)

      SC 13D/A - POINT Biopharma Global Inc. (0001811764) (Subject)

      12/20/23 4:38:39 PM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by POINT Biopharma Global Inc.

      SC 13D - POINT Biopharma Global Inc. (0001811764) (Subject)

      11/6/23 1:47:33 PM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by POINT Biopharma Global Inc. (Amendment)

      SC 13D/A - POINT Biopharma Global Inc. (0001811764) (Subject)

      10/3/23 2:57:27 PM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by POINT Biopharma Global Inc. (Amendment)

      SC 13G/A - POINT Biopharma Global Inc. (0001811764) (Subject)

      2/14/23 12:00:46 PM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by POINT Biopharma Global Inc.

      SC 13G - POINT Biopharma Global Inc. (0001811764) (Subject)

      2/3/23 12:10:00 PM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by POINT Biopharma Global Inc. (Amendment)

      SC 13D/A - POINT Biopharma Global Inc. (0001811764) (Subject)

      11/22/22 4:21:03 PM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by POINT Biopharma Global Inc. (Amendment)

      SC 13D/A - POINT Biopharma Global Inc. (0001811764) (Subject)

      9/26/22 5:29:14 PM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by POINT Biopharma Global Inc.

      SC 13G - POINT Biopharma Global Inc. (0001811764) (Subject)

      9/26/22 4:54:45 PM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by POINT Biopharma Global Inc. (Amendment)

      SC 13D/A - POINT Biopharma Global Inc. (0001811764) (Subject)

      9/16/22 4:29:43 PM ET
      $PNT
      Biotechnology: Pharmaceutical Preparations
      Health Care